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Vitamin D (VTD) treatment is recommended in patients presenting diﬀerent causes of diseases. To treat these patients, physicians
rely on the diﬀerent available pharmaceutical forms present in their country. Unfortunately, even in a given country, there is no
consensus on the best way to treat the patients. In Belgium, VTD is mostly prescribed as ampoules containing 25,000 IU of VTD. In
this randomised controlled study, we evaluated whether four therapeutic schemes using multiples of 25,000 IU of VTD according
to basal vitamin D concentration were able to increase or maintain the 25(OH)D serum level above 30 ng/mL. We randomized
175 subjects who received the drug (n = 140) or placebo (n = 35). Total duration of the study was 12 weeks. Doses ranged from
4167 to 1667 IU/day. Blood sampling was performed at baseline and each 4 visits. In the treated (placebo) subjects, mean 25(OH)D
serum concentration was 18.7 (19.1) ng/mL at baseline and 31.5 (20.7) ng/mL at w-12. At the end of the study, 57.1% of the subjects
treated with VTD presented 25(OH)D serum concentration ≥30 ng/mL, whereas 94.3% were ≥20 ng/mL. In conclusion, the doses
administered were safe and increased or maintained the 25(OH)D concentration ≥20 ng/mL. However, concentrations ≥30 ng/mL
were only achieved in 57.1% of the subjects.
1. Introduction
Vitamin D de�ciency has recently been identi�ed as a world-
wide problem [1]. Indeed, the dietary sources of vitamin
D are scarce, the only really signi�cant ones being marine
fatty �sh, although egg yolk and some mushrooms could be
additional sources [2]. us, in humans, the major source
of vitamin D comes from the exposure of the skin to
sunlight. While, in tropical zones, UVB radiation is suﬃcient
throughout the year, it is absent for a signi�cant part of the
year in more northern (or southern) latitudes. In Belgium
(around 51∘ North), the UVB ray will be insuﬃcient to
allow the skin synthesis of vitamin D during approximately
6 months of the year. Hence, while all experts agree that
the 25-hydroxy vitamin D (25(OH)D) level is the correct
indicator of vitamin D status, they do not agree on the
25(OH)D level that should be used to de�ne vitamin D
suﬃciency. Indeed, the expert panels from the Endocrine
Society [3] or the Institute of Medicine (IOM) [4] have
recently released divergent recommendations on the use of
vitamin D. e recent report by the IOM indicates that a
25(OH)D level of 20 ng/mL is largely suﬃcient and the RDIs
set forth should be suﬃcient for 97.5% of the population
to achieve that level whereas the Endocrine Society group
considers that the optimal 25(OH)D level formusculoskeletal
health should be 30 ng/mL and more in individual patients.
It should be considered that the IOM cutoﬀ is intended for
public health recommendations while the Endocrine Society
group targets its recommendations on patient care and
considers that vitamin D de�ciency (what should be avoided
in any patient) corresponds to 25(OH)D levels <20 ng/mL
and insuﬃciency (what may be deleterious for a signi�cant
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proportion of patients) to levels of 20 to 30 ng/mL. Now,
considering a threshold of 30 ng/mL, but even with the more
conservative IOM cutoﬀ of 20 ng/mL, insuﬃcient vitamin
D status is highly frequent. is can easily be understood
if one considers that the usual daily intakes of vitamin D
are not higher than 200 IU (and oen much lower) [5, 6]
whereas the most conservative recommendations of the IOM
are of 600 IU for adults up to 70 years and 800 IU for those
older. Taking that into consideration, one might consider
that a moderate supplementation without prior evaluation of
vitamin D status is necessary at the population level to ful�l
this recommendation. Now, there are some groups of patients
for whom many experts consider that a certain reasonably
evidence-based range of 25(OH)D concentration should be
targeted for optimal eﬀects of vitamin D. In these patients,
we [7], like many others [3, 8] consider that 25(OH)D should
be measured, and vitamin D supplementation should be
prescribed according to the measured serum level (higher
dosages in those with lower 25(OH)D concentrations). is
mostly apply to musculoskeletal eﬀects of vitamin D and
concern patients with, or at risk of, osteoporosis, chronic
kidney disease, primary hyperparathyroidism, intestinalmal-
absorption, and so on… for whom we use to target concen-
trations of 30–60 ng/mL. Daily dosages (600 to 4000 IU/day
for example) may be preferred as they are theoretically more
physiologic, but they usually suﬀer from poor compliance.
Although it has become usual practice to avoid very large
spaced out doses such as 500,000 IU vitamin D3 once a year
due to the results of a recent RCT [9], many physicians and
patients prefer intermediate doses given at intervals between
one week and one to two months. In Belgium, one of the
major source of pharmaceutical vitamin D supplementation
is the D-Cure (SMB Laboratories, Belgium), an oily solution
containing 25,000 IU of cholecalciferol per ampoule. is
drug is largely prescribed to correct vitamin D de�ciency,
but there is actually no validated treatment scheme. Several
protocols using doses of 50,000 IU vitamin D2 or D3 [1,
8] or 100,000 IU vitamin D3 [10] have been tested, but
to our knowledge, only one paper has reported the results
of supplementation with doses of 25,000 IU vitamin D3
[11]. In this randomised, parallel, double-blinded, placebo-
controlled study, we aimed to evaluate whether four thera-
peutic schemes that used diﬀerent doses of D-Cure according
to basal vitamin D concentration were able to increase or
maintain (depending on the baseline level) the 25(OH)D
serum level above 30 ng/mL.
2. Methods
2.1. Methodology. e study took place between the 23rd of
January and the 22nd of July, 2011. More than two hundred
subjects were screened within 14 days prior to starting the
study. ose who met all inclusion and none of the exclusion
criteria were randomized to one of the four strata based on
their baseline 25(OH)D serum concentration. e subjects
took the study medication under the supervision of the study
personnel at Visit 2 (week 0), Visit 3 (week 2), Visit 4 (week
4), and Visit 5 (week 8). e total duration of the study was
12 weeks with an 8-week period of supplementation followed
by a 4-week period without supplementation. Blood sam-
ples for measurement of 25(OH)D concentration, calcium,
phosphorus, and albumin were collected at each visit aer
an overnight fast and before next the vitamin D dose. We
includedCaucasian (de�ned as European andNorthAfrican)
male or female subjects over 50 years old with a body mass
index between 18 kg/m2 and 35 kg/m2 whowere able to com-
ply with all study procedures. ey gave written, informed
consent to participate in this trial. e exclusion criteria
were past or current history of any immunological, neoplasic,
endocrine, haematological, hepatic, renal, gastrointestinal,
neurological, or psychiatric abnormalities or medical dis-
ease. Subjects who used UV light solarium 2 weeks before
the screening visit or planned to travel outside European
countries during the study were excluded. We also excluded
patients under treatment with drugs that may interfere with
vitamin D metabolism (e.g., phenobarbital, phenytoin, and
glucocorticoids) and those with past or current history of
granulomatosis, especially sarcoidosis, urinary lithiasis, and
osteomalacia. Finally, patients who presented a 25(OH)D
concentration >60 ng/mL, serum creatinine >150𝜇𝜇mol/L
and albumin corrected serum calcium >2.65mmol/L (cor-
responding to 10.6mg/dL) at screening were also excluded,
as well as those with any sensitivity or allergy to any of the
products used in the study or a history of drug and/or alcohol
abuse.
2.1.1. Randomisation. At the baseline/randomisation visit
(Visit 2), aer con�rmation that the patients met all eligibility
criteria for the study, they were randomized and assigned
a randomisation number by an interactive web response
System (IWRS). A central, electronic, balanced, permuted
blocks randomisation were used. Patients were assigned at
random to placebo or vitamin D treatments of the 4 possible
groups. e IWRS will randomize a subject to either test or
placebo according to a 4 : 1 ratio. It was a block randomization
(blocks size of 5) strati�ed by subgroup.
e objective of this randomization was to obtain 50
patients in each group (40 to D-CURE treatment and 10
to placebo). When the objective was attained in a group,
no more inclusion was accepted in that group. Finally, only
the objective in group with 25(OH)D level >30 ng/mL was
not attained. In fact, only 20 patients were randomized to
receive vitamin D and 5 to placebo in that group, due to
the fact that the patients with 25(OH) level >30 ng/mL are
rare in the Belgium population. In total, 175 patients have
been enrolled (140 in treatment group and 35 in the placebo
group). e reasons of screening failures were BMI > 35
(exclusion criteria; 1 subject), patient consent withdrawn (1
subject), HCV positive (1 subject), and hypothyroidism (1
subject).
2.1.2. Treatment Scheme. At the end of the screening phase,
175 subjectswere selected. 140were assigned to receive theD-
Cure and 35, the placebo according to this scheme received.
Group 1. Subjects with baseline serum concentrations of
25(OH)D ≤ 10 ng/mL. Intake: 3 ampoules taken at
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week 0 and 2 followed by 2 ampoules at week 4 and 8
(total intake: 250,000 IU; 𝑛𝑛 𝑛 𝑛𝑛) or placebo (𝑛𝑛 𝑛 𝑛𝑛).
Group 2. Subjects with baseline serum concentrations of
25(OH)D > 10 ng/mL and ≤20 ng/mL. Intake: 3
ampoules taken at week 0 followed by 2 ampoules at
week 2 and 1 ampoule at week 4 and 8 (total intake:
175,000 IU; 𝑛𝑛 𝑛 𝑛𝑛) or placebo (𝑛𝑛 𝑛 𝑛𝑛).
Group 3. Subjects with baseline serum concentrations of
25(OH)D > 20 ng/mL and ≤30 ng/mL. Intake: 2
ampoules taken at week 0 followed by 1 ampoule at
week 2, 4, and 8 (total intake: 125,000 IU; 𝑛𝑛 𝑛 𝑛𝑛) or
placebo (𝑛𝑛 𝑛 𝑛𝑛).
Group 4. Subjects with baseline serum concentrations of
25(OH)D > 30 ng/mL and ≤60 ng/mL. Intake: 1
ampoule taken at week 0, 2, 4, and 8 (total intake:
100,000 IU; 𝑛𝑛 𝑛 𝑛𝑛) or placebo (𝑛𝑛 𝑛 𝑛).
e treatment schemes are summarized in Table 1. ese
schemes were chosen on the basis of the relationship between
a received daily dose of vitamin D3 and the subsequent
increase in the 25(OH)D serum level that had been published
previously. As, according to a rule of thumb, a daily dose of
1,000 IU vitaminD3was considered to increase the 25(OH)D
level by approximately 7 to 10 ng/mL [12], we decided to give
cumulative doses over the 8-week period of supplementa-
tions (60 days) that were approximately equivalent to 4,000,
3,000, and 2,000 IU/day in those with a baseline 25(OH)D
concentration <10 ng/mL, between 10 and 20 ng/mL, and
between 20 and 30 ng/mL, respectively. As we were using
25,000 IU doses, this translated in practice into 250,000 IU
over the 8-week period, corresponding to 4167 IU/day in
group 1 subjects, 175,000 IU corresponding to 2917 IU/day
in group 2, and 125,000 IU corresponding to 2083 IU/day in
group 3. For group 4 subjects, we arbitrarily decided to give
one ampoule every otherweek corresponding to 1667 IU/day.
For practical reasons, the number of takings of vitamin D3
ampoules was limited to four, so that the study personnel
was able to be present at each taking, ensuring an optimal
compliance.
We used the DiaSorin Liaison (Stillwater, MN, USA) for
25(OH)D determination. In our lab, intra-, and interassay
coeﬃcient of variation are <5% and <10%, respectively.
e functional detection limit is 8 ng/mL serum calcium;
phosphorus and albumin concentrations were evaluated with
the Roche Modular instrument (Mannheim, Germany).
2.2. Statistical Methods. We used the raw SAS Version 9.1
or higher soware to compute the results. All statistical
tests were performed two sided, and a 𝑃𝑃 value less than
5% was considered as statistically signi�cant. Mean changes
from baseline to week 12 was calculated with ANOVA. e
percentages of subjects reaching 25-hydroxyvitaminD serum
concentrations ≥20 ng/mL and ≥30 ng/mL at the end of the
study were analysed by means of a chi-square test comparing
D-CURE and placebo. For the main continuous baseline
characteristics age, and BMI, an ANOVA was performed,
and for the binomial baseline variable sex, we used a
Cochran-Mantel-Haenszel Test. All safety data obtained in
this study was tabulated with descriptive statistics. Compar-
isons between treatment groups were based on descriptive
statistics.
is trial was approved by the relevant Independent
Ethics Committee (IEC) and the Competent Authority prior
to the start of the study and conducted in compliance
with the protocol, with the ICH Harmonized Tripartite
Guideline, Guideline for Good Clinical Practice, Step 5
(CPMP/ICH/135/95), the applicable regulatory requirements
based on EU Directive 2001/20/EC and EU GCP Directive
(2005/28/EC), and the Declaration of Helsinki (World Med-
ical Association) in its revised edition.
3. Results
One hundred and seventy-�ve subjects completed the study.
eir demographics are shown in Table 2. As treatment
was taken under the supervision of the study personnel,
observance was of 100%.
In the treated subjects, the mean 25(OH)D serum con-
centration was 18.7 ng/mL at baseline and 31.5 ng/mL at
week 12, with amean change to baseline of 𝑛𝑛.9±𝑛𝑛.7 ng/mL.
In the placebo group, the mean 25(OH)D serum concentra-
tion was 19.1 ng/mL at baseline and 20.7 ng/mL at week 12;
the mean change to baseline was 𝑛.7 ± 6.3 ng/mL. e mean
25(OH)D serum concentration at all timepoints is shown in
Table 3 for each group. ere was a signi�cant increase in
25(OH)D levels at week 12 for all treated groups compared to
baseline (𝑛9.7 ± 9.𝑛, 𝑛𝑛.8 ± 8.𝑛, 9.𝑛 ± 8.9, and 𝑛.𝑛𝑛 ± 9.8 ng/mL
for theGroup 1, 2, 3, and, 4, resp.). During the study there was
a signi�cant di�erence between the vitamin D and placebo
groups in the 25(OH)D concentrations at week 2, 4, 8, and 12
(𝑃𝑃 < 𝑛.𝑛𝑛𝑛 for the global group analysis).
e highest serum 25(OH)D concentration (68 ng/mL)
was observed at week 12 in one subject of the group 4, whose
basal level was of 48 ng/mL.
At the end of the study, (week 12) 57.1% (𝑛𝑛 𝑛 8𝑛) of
subjects in the vitamin D group had a 25(OH)D serum con-
centration ≥30 ng/mL, and 94.3% (𝑛𝑛 𝑛 𝑛3𝑛), a concentration
≥20 ng/mL. In the placebo group, 20.0% (𝑛𝑛 𝑛 7) had a
25(OH)D serum concentration ≥30 ng/mL and 54.3% (𝑛𝑛 𝑛
𝑛9) ≥20 ng/mL. e number of subjects that did not reach
25(OH)D levels of 30 ng/mL or 20 ng/mL at each timepoint
is shown in Table 3 and Figure 1 for each treated and placebo
group separately. e lower number of subjects that did not
reach 25(OH)D serum concentrations of ≥30 ng/mL at week
12 was seen in group 3 subjects (25%, 𝑛𝑛 𝑛 𝑛𝑛/40). ere were
25/40 (62%) subjects and 24/40 (60%) subjects who did not
reach serum concentrations of 25(OH) vitaminD ≥30 ng/mL
at week 12 in the groups 1 and 2, respectively.
Altogether 106 of the 140 subjects of the vitamin D group
(75.71%) and 11 of the 35 subjects treated with placebo
(31.43%) had a serum 25(OH)D concentration of ≥30 ng/mL
at one or more time points during the study. e highest
number of subjects was in subgroup 3. In this group, 97.5%
of the subjects achieved a serum 25(OH)D concentration of
≥30 ng/mL in one or more visit, but only 77.5% of them had
a serum 25(OH)D concentration of ≥30 ng/mL at the end of
the study.
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T 1: Treatment scheme with diﬀerent intakes of vitamin D according to the 25(OH)D basal level of the subjects.
Week 0 Week 2 Week 4 Week 8 Total
Group 1
≤10 ng/mL
Treated group (𝑛𝑛 𝑛 𝑛𝑛) 75,000UI 75,000UI 50,000UI 50,000UI 250,000UI
Placebo (𝑛𝑛 𝑛 𝑛𝑛) placebo placebo placebo placebo placebo
Group 2
>10 ng/mL and ≤20 ng/mL
Treated group (𝑛𝑛 𝑛 𝑛𝑛) 75,000UI 50,000UI 25,000UI 25,000UI 175,000UI
Placebo (𝑛𝑛 𝑛 𝑛𝑛) placebo placebo placebo placebo placebo
Group 3
>20 ng/mL and ≤30 ng/mL
Treated group (𝑛𝑛 𝑛 𝑛𝑛) 50,000UI 25,000UI 25,000UI 25,000UI 125,000UI
Placebo (𝑛𝑛 𝑛 𝑛𝑛) placebo placebo placebo placebo placebo
Group 4
>30 ng/mL and ≤60 ng/mL
Treated group (𝑛𝑛 𝑛 𝑛𝑛) 25,000UI 25,000UI 25,000UI 25,000UI 100,000UI
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F 1: Evolution of the percentages of patients presenting 25(OH)D values <20 and <30 ng/mL throughout the study, according to their
treatment scheme.
ere were no signi�cant changes to baseline seen in the
mean plasma phosphorus and calcium concentrations during
the study.emean change to baseline at week 12 for plasma
phosphorus was −0.29 mg/dL (±1.960) in subjects treated
with SMBD-CURE and−0.26 mg/dL (±0.584) in the placebo
group. e mean change to baseline at week 12 for plasma
calciumwas 0.00mg/dL ± 0.378 in subjects treated with SMB
D-CURE and 0.02mg/dL ± 0.259 in the placebo group. We
did neither observe hypercalcemia nor kidney stone during
the study.
4. Discussion
We performed a trial to test several schemes of supplementa-
tion with ampoules containing 25,000 IU vitamin D3 in sub-
jects 50 years of age and older, based on their baseline serum
concentration of 25(OH)D. e main strengths of this study
are its double-blinded, placebo-controlled nature, allowing
to control for possible confounders such as season-, or diet-
related changes in the 25(OH)D level, and the supervision by
the study staﬀ of the administration of all vitamin D3 doses
allowing for a compliance of 100%.
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e concentration of 25(OH)D in serumwas signi�cantly
increased aer treatment with D-CURE compared to placebo
for the total analysis. As this study took place during a part
of spring, it is important to note that we did not observe
any signi�cant increase in the placebo group, suggesting that
these increases in the treated group are only due to the
treatment.
At week 12 of the study, that is one month aer a
60-day supplementation period with doses of vitamin D3
corresponding to 1667 to 4167 IU/day, the mean change
from baseline in the diﬀerent subgroups ranged from +2.5
to +19.7 ng/mL. is was somewhat lower than the expected
increase of 7 to 10 ng/mL in the 25(OH)D level for every
1,000 IU vitamin D3 per day, according to Heaney [12]. e
25(OH)D increase in our study was also lower than what
could have been predicted from a more recent meta-analysis
where the average increase during diﬀerent RCT or open
trials was 0.78 ng/mLper 40 IUof vitaminD3 supplement per
day in Caucasian subjects over 50 yr old, albeit with a great
variability [13]. In this meta-analyse, the authors underlined
diﬀerent sources of between-trial variability. Poor adherence
to supplementation, oen due to coadministration of calcium
supplements, use of vitamin D2 instead of vitamin D3, and
high proportion of overweight subjects included in the trial
were identi�ed as potential causes for a weak increase in
the 25(OH)D serum level. ese reasons do not apply to
the present study in which compliance was 100%, calcium
supplements were not provided, vitamin D3 was used, and
the mean BMI was close to 26 kg/m2 with very few obese
(BMI > 30) subjects. Another potential cause of variability
in the 25(OH)D response to vitamin D supplementation
among studies is the use of various 25(OH)D assays. In
the present study, we used the DiaSorin Liaison assay, an
automated assay widely used worldwide and for which the
results of the external pro�ciency testing DE�AS samples in
our laboratory are very close of the all laboratory trimmed
mean (ALTM).
While most of the vitamin D-treated subjects reached
a 25(OH)D serum concentration of 20 ng/mL or more,
only 42.5% of those with baseline concentrations below
10 ng/mL, 47.5% of those with baseline concentrations of
10 to ≤20 ng/mL, and 77.5% of those with a baseline level
of 20 to ≤30 ng/mL achieved a 25(OH)D concentration of
≥30 ng/mL at week 12. Furthermore, only 65.0% of those
who had concentrations of ≥30 ng/mL at week 0 had still
such a value at week 12 aer treatment. Overall, this suggests
that the doses of vitamin D3 administered in the present
study were insuﬃcient to achieve or maintain the 30 ng/mL
target in a signi�cant proportion of the included subjects. It
must be underlined that the dose administered to the subjects
with a baseline serum level ≤10 ng/mL was already very close
(slightly above in fact) to the upper safety limit (UL) of
4,000 IU/day de�ned by the IOM[4].us, if a 25(OH)D level
of 30 ng/mLormore is targeted in future studies, higher doses
than the IOM UL should be used.
At week 12, change from baseline in the 25(OH)D con-
centration of the placebo groups ranged from −8.20 to
+4.30 ng/mL. e negative change was observed in the
subgroup with baseline 25(OH)D > 30 ng/mL and con�rms
that even if this target level is reached, a maintenance dose
is usually required to sustain the serum 25(OH)D above
30 ng/mL.
e maximum serum 25(OH)-vitamin D concentra-
tion (68 ng/mL) was observed at week 12 and is far from
150 ng/mL, generally considered as the potentially “toxic”
limit. We did not observe clinically signi�cant change in the
plasma calcium and phosphorus concentrations.
In conclusion, this study explored the change in serum
25(OH)D concentrations in subjects with diﬀerent baseline
concentrations of 25(OH)D who received diﬀerent doses
of vitamin D. e current doses administered were safe
and produced a signi�cant change compared to placebo,
increasing or maintaining (depending on the baseline level)
the 25(OH)D concentration ≥20 ng/mL. However, serum
concentrations of 25(OH)D ≥ 30 ng/mL were only achieved
in 57.1% of the subjects receiving the vitamin D, indicating
that the dosesmay need to be increased in subsequent studies
where this concentration will be targeted.
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